BioWorld MedTech

July 23, 2014

Boston Scientific receives PMA for its Rebel Platinum Chromium BMS

Despite the adoption rates of drug-eluting stents (DES), device makers haven't totally abandoned bare metal stents (BMS). One only has to look at Boston Scientific's (Natick, Massachusetts) most recent product approval as evidence. Read More

World in Review: Oraya Therapeutics expanding AMD wet therapy into Europe

FDA releases documents under IMDRF's single audit program

EPs in Europe gain access to new FlexAbility catheter from St. Jude

Daily M&A: Kindred ups its offer for Gentiva to $17.25 a share, subject to 'diligence'

Agreements/Contracts: Christie NHS to join consortium to develop radiotherapy system

Patent Watch: Neodyne Biosciences receives Korean patent for treatment of Keloids

Hit Bits: New security consulting services aim to protect medical device cybersecurity

Briefly noted

Products

People in Places

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...